Analysts Set Omeros Co. (NASDAQ:OMER) Target Price at $22.50

Shares of Omeros Co. (NASDAQ:OMER) have earned an average recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $22.50.

A number of equities research analysts have recently commented on OMER shares. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. D. Boral Capital started coverage on shares of Omeros in a research note on Monday. They issued a “buy” rating and a $36.00 target price on the stock. Rodman & Renshaw assumed coverage on shares of Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 target price for the company. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a report on Thursday, November 14th.

Hedge Funds Weigh In On Omeros

A number of large investors have recently made changes to their positions in the stock. Wellington Management Group LLP purchased a new stake in shares of Omeros in the 3rd quarter valued at about $305,000. HighTower Advisors LLC boosted its stake in shares of Omeros by 7.2% in the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 4,000 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after buying an additional 31,081 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in Omeros during the 2nd quarter valued at about $105,000. 48.79% of the stock is owned by institutional investors.

Omeros Price Performance

OMER opened at $10.00 on Monday. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60. The company has a market capitalization of $579.50 million, a price-to-earnings ratio of -4.33 and a beta of 1.96. The firm’s fifty day moving average price is $7.33 and its two-hundred day moving average price is $5.28.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.